Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy predominantly driven by KRAS mutations, with the KRAS G12D mutation being the most prevalent. Historically considered "undruggable," the KRAS oncoprotein has recently become a viable therapeutic target. Zoldonrasib (RMC-9805) is an emerging, first-in-class, orally bioavailable, mutant-selective covalent inhibitor designed to target the active, GTP-bound state of KRAS G12D. By forming a unique tri-complex with the chaperone protein cyclophilin A, Zoldonrasib acts as a molecular glue to covalently modify the mutant aspartic acid residue (Asp-12), thereby disrupting downstream oncogenic signaling. Preclinical studies demonstrate that RMC-9805 effectively induces apoptosis and drives tumor regression in PDAC models. Early clinical data from Phase I trials (such as NCT06040541) indicate a favorable safety profile and encouraging preliminary antitumor activity, including deep reductions in circulating tumor DNA (ctDNA). This review synthesizes current literature on Zoldonrasib, detailing its pharmacological activity, molecular mechanism, structure-activity relationship, current limitations, and future perspectives in the treatment of KRAS G12D-mutated PDAC.
1. Introduction
Pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC), is one of the most aggressive and lethal malignancies, characterized by a 5-year survival rate of approximately 10-13% [1][2]. The disease is genetically defined by a high frequency of somatic mutations, with oncogenic mutations in the Kirsten rat sarcoma viral oncogene (KRAS) occurring in over 90% of PDAC cases [2]. Among these, the KRAS G12D mutation is the most prevalent, accounting for approximately 40% of all KRAS alterations in PDAC, and is strongly associated with poor clinical outcomes and tumor dependence for survival [1][2].
For decades, KRAS was deemed "undruggable" due to its picomolar affinity for GTP and the absence of deep structural pockets suitable for allosteric small-molecule binding [2]. While recent breakthroughs led to the FDA approval of covalent inhibitors targeting the KRAS G12C mutation (e.g., sotorasib and adagrasib), this specific mutation is rare in PDAC, occurring in only 1-3% of patients [1][2]. Consequently, there is a critical unmet need for therapies targeting the G12D variant. Zoldonrasib (RMC-9805), developed by Revolution Medicines, has emerged as a highly promising, first-in-class, oral inhibitor specifically designed to target the active state of KRAS G12D, offering new hope for patients with PDAC [1][2][3].
2. Pharmacological Activity
Zoldonrasib (RMC-9805) has demonstrated robust pharmacological activity in both preclinical and early clinical settings. In preclinical in vitro models, RMC-9805 effectively inhibits cell proliferation, induces apoptosis, and suppresses RAS pathway activity in KRAS G12D-mutant cancer cell lines [1][2]. In vivo, mouse xenograft models of KRAS G12D-mutant tumors treated with RMC-9805 exhibited significant tumor regression, eliciting objective responses in 7 out of 9 PDAC models [2].
Clinically, Zoldonrasib is currently being evaluated in the Phase I/Ib trial NCT06040541 for patients with advanced KRAS G12D-mutant solid tumors [1][2][3]. Preliminary data from this study show encouraging antitumor activity. In patients with KRAS G12D PDAC, RMC-9805 induced early and deep reductions in KRAS G12D circulating tumor DNA (ctDNA) [1]. Across early studies of solid tumors (including non-small cell lung cancer), the drug demonstrated an objective response rate (ORR) of 61% and a disease control rate (DCR) of 89% [3]. Furthermore, RMC-9805 has shown an acceptable safety and tolerability profile; no grade 4 or 5 adverse events (AEs) were reported in early PDAC cohorts, with the most common grade 1 or 2 AEs being nausea, diarrhea, vomiting, and rash [1].
3. Molecular Mechanism of Action
Zoldonrasib (RMC-9805) operates via a highly innovative mechanism of action as a selective RAS(ON) G12D inhibitor [3]. KRAS mutations like G12D impair intrinsic GTPase activity and evade GTPase-activating proteins (GAPs), locking the KRAS protein in a constitutively active, GTP-bound ("ON") state that continuously drives downstream oncogenic signaling pathways, such as RAF-MEK-ERK and PI3K-AKT [2].
To target this active state, RMC-9805 functions as a "molecular glue." It first binds to cyclophilin A, a ubiquitous cellular chaperone protein. The formation of this binary complex induces a conformational change that enables it to selectively bind to the GTP-bound active state of KRAS G12D [2][3]. This tri-complex formation brings the inhibitor into close proximity with the mutant Asp-12 residue, allowing for covalent modification and subsequent steric blockade of KRAS interactions with downstream effector proteins, thereby halting oncogenic signaling [3].
4. Structure-Activity Relationship (SAR)
The design of KRAS G12D inhibitors presents a unique biochemical challenge compared to KRAS G12C inhibitors. While the G12C mutation provides a highly reactive cysteine residue that readily forms covalent bonds with inhibitors (e.g., sotorasib), the G12D mutation replaces glycine with aspartic acid (Asp-12) [2][3]. The carboxylate group of aspartic acid is a weak nucleophile, making traditional covalent targeting exceptionally difficult [3].
Zoldonrasib overcomes this structural hurdle through its tri-complex mechanism. By recruiting cyclophilin A, the compound creates a highly specific structural interface that perfectly accommodates the GTP-bound conformation of KRAS G12D. This structural arrangement facilitates the necessary proximity and orientation to achieve covalent modification of the weakly nucleophilic Asp-12 residue [3]. This mechanism ensures that RMC-9805 is highly mutant-selective, effectively targeting the KRAS G12D(ON) state while sparing wild-type KRAS and other mutant variants [1][2].
5. Current Limitations
Despite its promise, the clinical development of Zoldonrasib faces several limitations. First, the clinical data available are still in the preliminary phases (Phase I/Ib), meaning that long-term efficacy, durability of response, and comprehensive safety profiles in larger PDAC patient populations remain to be fully established [1].
Second, the emergence of therapeutic resistance is a universal challenge in KRAS-targeted therapies. Resistance mechanisms to KRAS inhibitors in PDAC can include secondary mutations within the KRAS binding pocket, amplification of the mutant allele, and the reactivation of downstream pathways (such as ERK rebound) or parallel signaling networks (like the PI3K/AKT pathway) [1][2]. Additionally, PDAC is characterized by a dense, desmoplastic, and immunosuppressive tumor microenvironment (TME). This stroma can physically limit drug delivery and create hypoxic niches that promote metabolic reprogramming and epithelial-to-mesenchymal transition (EMT), further driving resistance to targeted agents like RMC-9805 [1][2].
6. Future Perspectives
To maximize the clinical utility of Zoldonrasib and overcome anticipated resistance, future strategies are heavily focused on combination therapies. Preclinical evidence suggests that combining RMC-9805 with immune checkpoint inhibitors significantly improves anti-tumor responses in KRAS G12D-mutant PDAC models, likely by modulating the immunosuppressive TME [2].
Clinical trials are already expanding to evaluate RMC-9805 in various combination regimens. For instance, the NCT06445062 trial is investigating RMC-9805 in combination with standard-of-care chemotherapies (such as 5-fluorouracil-based regimens or gemcitabine plus nab-paclitaxel) and targeted agents like cetuximab or the pan-RAS inhibitor RMC-6236 in gastrointestinal solid tumors [1]. Furthermore, integrating biomarker-guided approaches—such as monitoring on-treatment ctDNA dynamics—will be crucial for identifying patients most likely to benefit and for detecting early signs of resistance [1][2]. Continued exploration of combinations targeting upstream regulators (e.g., SHP2 or SOS1) or parallel metabolic pathways holds significant promise for extending survival in patients with KRAS G12D-driven PDAC [1][2].
